Human Epidermal Growth Factor Receptor 2–Mutant Non–Small-Cell Lung Cancer: Continued Progress But Challenges Remain
Mené sur 45 patients atteints d'un cancer du poumon non à petites cellules de stade avancé et présentant une mutation HER2 (âge médian : 64,5 ans), cet essai non randomisé de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité d'un traitement combinant trastuzumab, pertuzumab et docétaxel
The management of non–small-cell lung cancer (NSCLC) continues to evolve at a rapid pace, aided in large part by the clinical development of targeted therapies aimed at genetic alterations in oncogenic drivers. Indeed, within the past 2 years alone, the US Food and Drug Administration (FDA) has granted regulatory approvals for agents directed against three new targets (KRAS, MET, and RET), bringing the total number of distinct molecularly defined targets with approved therapies in NSCLC up to nine.1 Nonetheless, it has become clear that the discovery of an oncogenic driver does not necessarily predict the straightforward development of an effective targeted therapy, as exemplified by efforts to target human epidermal growth factor receptor 2 (HER2) in NSCLC.
Journal of Clinical Oncology , éditorial, 2021